Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules (Q45418478)

14 December 2017

title

Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules (English)

1 reference

14 December 2017

1 reference

Shahriar Absar

1

1 reference

14 December 2017

Kamrun Nahar

2

1 reference

14 December 2017

Suna Choi

3

1 reference

14 December 2017

Fakhrul Ahsan

4

1 reference

14 December 2017

Victor C Yang

5

1 reference

14 December 2017

Young M Kwon

6

1 reference

14 December 2017

publication date

27 August 2013

1 reference

Journal of Biomedical Materials Research Part A

14 December 2017

published in

1 reference

14 December 2017

volume

102

1 reference

14 December 2017

issue

8

1 reference

14 December 2017

page(s)

2481-2490

1 reference

Human serum albumin: from bench to bedside

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Defining the role of insulin detemir in Basal insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Size and dynamics of caveolae studied using nanoparticles in living endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Impact of albumin on drug delivery--new applications on the horizon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Structure of the fibrinogen γ-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Synthesis and characterization of stearyl protamine and investigation of their complexes with DNA for gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Application of "ATTEMPTS" for drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

PEGylation of human serum albumin: reaction of PEG-phenyl-isothiocyanate with protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

Gp60 Activation Mediates Albumin Transcytosis in Endothelial Cells by Tyrosine Kinase-dependent Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.34916

21 January 2018

Identifiers

DOI

10.1002/JBM.A.34916

1 reference

14 December 2017

1 reference